GEN Exclusives

More »

GEN News Highlights

More »
Jan 28, 2009

Omeros Achieves $3.1M Milestone under a Schizophrenia Partnership with The Stanley Medical Research Institute

  • Omeros was awarded $3.1 million in a second tranche of equity and grant funding from The Stanley Medical Research Institute (SMRI) to support late-stage preclinical development of its schizophrenia drug candidates. The funds serve as a milestone payment to Omeros for having successfully met preclinical compound optimization criteria.

    Omeros' schizophrenia product candidates inhibit the phosphodiesterase 10 (PDE10) enzyme. “We believe that our program could provide product candidates that have benefits not offered by existing antipsychotics and we are working to advance into clinical trials next year,” says Gregory A. Demopulos, M.D., chairman and CEO.

    In December 2006, Omeros entered into an agreement with SMRI to develop its PDE10 inhibitors through Phase I trials. The $2.6 million first tranche of grant and equity funding was received at signing of the deal, and Omeros stands to earn another $3.3 million.

    ---

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?